1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68D14D17C87C4AA3D0025876C004CE9C9
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-managing-hostile-stakeholders-during-launch-breakthrough-new-medicine-winning-patients?OpenDocument
18
19OpenDocument
2052.90.49.108
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Winning Patients to Your Side

ID: 5703


Features:

30 Info Graphics

2 Data Graphics

10+ Metrics

22 Narratives


Pages/Slides: 39


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine: Winning Patients to Your Side”

STUDY OVERVIEW

Winning patient support is key for pharma companies set to launch a novel breakthrough medicine. Some launches involve products that draw controversy, be it the condition being treated, the pricing of the product or other issues.


Thus sometimes launch leaders must tread carefully to build credibility among patients and to respond to potential adversaries. Forward-looking pharma companies have started developing rapid response teams to map and engage the full range of hostile stakeholder groups.

Best Practices, LLC engaged senior launch leadership from pharma companies and conducted extensive secondary research to identify effective strategies for managing hostile stakeholders during the launch of a breakthrough new medicine.

The study probes key aspects including: turning citizens into political influencers; working with patient advocacy groups; and winning patients to your side.

KEY TOPICS

  • Turning Citizens into Political Influencers
  • Working with Patient Advocacy Groups
  • Winning Patients on Your Side

SAMPLE KEY FINDINGS

  • Find The Temperate Voices: Find moderate voices in special interest groups to gain footholds and build relationships.
  • Arm Patients with Fact: Celebrity spokespeople can be a valuable channel by which to deliver education to patients who may not tune in to other healthcare outlets.

METHODOLOGY

Best Practices, LLC engaged and examined front-line executives at 11 companies across 9 therapeutic areas to conduct this analysis on hostile stakeholder management. Extensive secondary research was also conducted to identify industry best practices.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Bayer; Boehringer Ingelheim; Eli Lilly and Company; Gilead Sciences; GlaxoSmithKline ; Johnson & Johnson; Merck; Pfizer; Roche; Sprout Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.